Genetic Technologies Ltd.
GENE
GENE was delisted on the 16th of October, 2024.
15 hedge funds and large institutions have $1.49M invested in Genetic Technologies Ltd. in 2021 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 4 closing their positions.
12% less funds holding
Funds holding: 17 → 15 (-2)
13% less capital invested
Capital invested by funds: $1.7M → $1.49M (-$216K)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
40% less call options, than puts
Call options by funds: $516K | Put options by funds: $864K
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$239K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$124K |
| 3 |
Jane Street
New York
|
+$70K |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
+$43K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$10K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$315K |
| 2 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$115K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$99K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$68.6K |
| 5 |
EGM
Engineers Gate Manager
New York
|
-$42K |
GENE Hedge Fund Activity: Q2 2021 in Review
15 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Genetic Technologies Ltd. (GENE) for Q2 2021, worth a combined $1.49M — down 13% from $1.7M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GENE and 2 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Morgan Stanley, adding an estimated $239K. The largest seller was Citadel Advisors, cutting an estimated $315K.
- 15 institutional investors held Genetic Technologies Ltd. (GENE) as of Q2 2021, down from 17 in Q1 2021.
- Funds reported $1.49M of Genetic Technologies Ltd. stock for Q2 2021, down 13% quarter-over-quarter.
- 2 funds opened new Genetic Technologies Ltd. positions in Q2 2021 and 4 closed out, a net change of -2 holders.
- The largest Genetic Technologies Ltd. buyer in Q2 2021 was Morgan Stanley, an estimated $239K added.
- The largest Genetic Technologies Ltd. seller in Q2 2021 was Citadel Advisors, an estimated $315K sold.
Based on aggregated 13F filings for Q2 2021.